Literature DB >> 30497790

Heat shock proteins: A dual carrier-adjuvant for an anti-drug vaccine against heroin.

Candy S Hwang1, Beverly Ellis1, Bin Zhou1, Kim D Janda2.   

Abstract

Heroin is a highly abused opioid that has reached epidemic status within the United States. Yet, existing therapies to treat addiction are inadequate and frequently result into rates of high recidivism. Vaccination against heroin offers a promising alternative therapeutic option but requires further development to enhance the vaccine's performance. Hsp70 is a conserved protein with known immunomodulatory properties and is considered an excellent immunodominant antigen. Within an antidrug vaccine context, we envisioned Hsp70 as a potential dual carrier-adjuvant, wherein immunogenicity would be increased by co-localization of adjuvant and antigenic drug hapten. Recombinant Mycobacterium tuberculosis Hsp70 was appended with heroin haptens and the resulting immunoconjugate granted anti-heroin antibody production and blunted heroin-induced antinociception. Moreover, Hsp70 as a carrier protein surpassed our benchmark Her-KLH cocktail through antibody-mediated blockade of 6-acetylmorphine, the main mediator of heroin's psychoactivity. The work presents a new avenue for exploration in the use of hapten-Hsp70 conjugates to elicit anti-drug immune responses.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant; Carrier protein; Heat shock protein; Heroin; Immunotherapy; Opioids; Vaccines

Mesh:

Substances:

Year:  2018        PMID: 30497790      PMCID: PMC6442938          DOI: 10.1016/j.bmc.2018.11.027

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  33 in total

1.  Dynamic vaccine blocks relapse to compulsive intake of heroin.

Authors:  Joel E Schlosburg; Leandro F Vendruscolo; Paul T Bremer; Jonathan W Lockner; Carrie L Wade; Ashlee A K Nunes; G Neil Stowe; Scott Edwards; Kim D Janda; George F Koob
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

Review 2.  Animal Models and the Development of Vaccines to Treat Substance Use Disorders.

Authors:  O Ohia-Nwoko; T A Kosten; C N Haile
Journal:  Int Rev Neurobiol       Date:  2016-03-07       Impact factor: 3.230

3.  Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial.

Authors:  Thomas R Kosten; Coreen B Domingo; Daryl Shorter; Frank Orson; Charles Green; Eugene Somoza; Rachelle Sekerka; Frances R Levin; John J Mariani; Maxine Stitzer; D Andrew Tompkins; John Rotrosen; Vatsal Thakkar; Benjamin Smoak; Kyle Kampman
Journal:  Drug Alcohol Depend       Date:  2014-04-16       Impact factor: 4.492

4.  A vaccine strategy that induces protective immunity against heroin.

Authors:  G Neil Stowe; Leandro F Vendruscolo; Scott Edwards; Joel E Schlosburg; Kaushik K Misra; Gery Schulteis; Alexander V Mayorov; Joseph S Zakhari; George F Koob; Kim D Janda
Journal:  J Med Chem       Date:  2011-06-30       Impact factor: 7.446

5.  Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial.

Authors:  Philippe H J Hoogsteder; Daniel Kotz; Paul I van Spiegel; Wolfgang Viechtbauer; Onno C P van Schayck
Journal:  Addiction       Date:  2014-06-03       Impact factor: 6.526

6.  Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling.

Authors:  Henriette Bendz; Sibylle C Ruhland; Maya J Pandya; Otmar Hainzl; Stefan Riegelsberger; Christoph Braüchle; Matthias P Mayer; Johannes Buchner; Rolf D Issels; Elfriede Noessner
Journal:  J Biol Chem       Date:  2007-08-07       Impact factor: 5.157

7.  Synergistic stimulation of antigen presenting cells via TLR by combining CpG ODN and poly(γ-glutamic acid)-based nanoparticles as vaccine adjuvants.

Authors:  Fumiaki Shima; Tomofumi Uto; Takami Akagi; Mitsuru Akashi
Journal:  Bioconjug Chem       Date:  2013-05-13       Impact factor: 4.774

8.  Development of a Clinically Viable Heroin Vaccine.

Authors:  Paul T Bremer; Joel E Schlosburg; Matthew L Banks; Floyd F Steele; Bin Zhou; Justin L Poklis; Kim D Janda
Journal:  J Am Chem Soc       Date:  2017-06-20       Impact factor: 15.419

9.  Flagellin as carrier and adjuvant in cocaine vaccine development.

Authors:  Jonathan W Lockner; Lisa M Eubanks; Jennifer L Choi; Jenny M Lively; Joel E Schlosburg; Karen C Collins; Daniel Globisch; Robin J Rosenfeld-Gunn; Ian A Wilson; Kim D Janda
Journal:  Mol Pharm       Date:  2015-01-07       Impact factor: 4.939

10.  A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse.

Authors:  Agnieszka Sulima; Rashmi Jalah; Joshua F G Antoline; Oscar B Torres; Gregory H Imler; Jeffrey R Deschamps; Zoltan Beck; Carl R Alving; Arthur E Jacobson; Kenner C Rice; Gary R Matyas
Journal:  J Med Chem       Date:  2017-12-29       Impact factor: 7.446

View more
  5 in total

Review 1.  Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Authors:  Marco Pravetoni; Sandra D Comer
Journal:  Neuropharmacology       Date:  2019-06-04       Impact factor: 5.250

2.  Heroin vaccine: Using titer, affinity, and antinociception as metrics when examining sex and strain differences.

Authors:  Candy S Hwang; Lauren C Smith; Cody J Wenthur; Beverly Ellis; Bin Zhou; Kim D Janda
Journal:  Vaccine       Date:  2019-06-05       Impact factor: 3.641

3.  Evaluation of a Dual Fentanyl/Heroin Vaccine on the Antinociceptive and Reinforcing Effects of a Fentanyl/Heroin Mixture in Male and Female Rats.

Authors:  E Andrew Townsend; Paul T Bremer; Kaycee E Faunce; S Stevens Negus; Alaina M Jaster; Hannah L Robinson; Kim D Janda; Matthew L Banks
Journal:  ACS Chem Neurosci       Date:  2020-04-22       Impact factor: 4.418

4.  Enhancement of a Heroin Vaccine through Hapten Deuteration.

Authors:  Tyson F Belz; Paul T Bremer; Bin Zhou; Beverly Ellis; Lisa M Eubanks; Kim D Janda
Journal:  J Am Chem Soc       Date:  2020-07-27       Impact factor: 15.419

5.  In silico design and in vitro expression of novel multiepitope DNA constructs based on HIV-1 proteins and Hsp70 T-cell epitopes.

Authors:  Elahe Akbari; Kimia Kardani; Ali Namvar; Soheila Ajdary; Esmat Mirabzadeh Ardakani; Vahid Khalaj; Azam Bolhassani
Journal:  Biotechnol Lett       Date:  2021-05-13       Impact factor: 2.461

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.